A report from Poland: treatment and non-treatment of defective newborns

The author and his colleagues surveyed pediatricians in Warsaw, Poland, to determine the doctors' attitudes toward treating infants with severe handicaps. They used a questionnaire originally designed by Australian researchers to survey pediatricians and compared their findings with those of the Australian study. Szawarski notes important differences between the approaches of Australian and Polish doctors to the treatment of handicapped newborns. Polish physicians tend to display an unconditional respect for life, a paternalistic attitude toward decision making, and an unwillingness to distinguish between ordinary and extraordinary means of prolonging life. Half the Polish respondents would be willing to preserve the lives of severely handicapped infants at all costs. Szawarski discusses six factors that may help to explain why Polish physicians have a different approach from that of their Western colleagues to the question of selective treatment of handicapped newborns.     

Immunosuppressive activity of antamanide and some of its analogues

In connection with our discovery of a strong immunosuppressive activity of cyclolinopeptide A (CLA), we investigated immunosuppressive properties of antamanide and a number of its analogues, including symmetrical antamanide, and compared them with the activities of cyclosporin A and CLA. The peptides were investigated by using plaque forming cell (PFC), graft-versus-host (GvH), delayed type hypersensitivity (DTH), and autologous rosette formation cell (ARFC) tests. Antamanide and symmetrical antamanide exhibit an immunosuppressive activity lower than CLA. Linear antamanide fragments are also active. At higher concentrations of the latter peptides, toxic effects occur.